The simple version
Psilocybin and anorexia nervosa is one of the most sensitive areas in psychedelic research. It is also one of the easiest areas to overstate.
The honest public message is simple: researchers are studying psilocybin-assisted therapy for anorexia, but it is not proven treatment. The published studies are early. They use screened participants, supervised sessions, psychological support, and follow-up. They do not support self-treatment or microdosing claims.
Anorexia nervosa can be life-threatening. NIMH notes that anorexia can lead to serious health consequences and that people with anorexia are at risk of death from starvation-related medical complications and suicide. [1] Government Eating Disorders: What You Need to Know Link → That medical reality changes how this topic must be handled.
Why anorexia is not just about food
A person looking from the outside may think anorexia is only about eating less. That misses the deeper issue.
For many people, anorexia can involve fear, control, body-image distress, shame, rigid rules, and a painful sense that the eating disorder is helping them stay safe or in control. Some researchers use terms like “cognitive rigidity” for this. In KISS language, that means getting stuck in a pattern that is hard to loosen.
That is one reason psilocybin has attracted research interest. The question is not whether psilocybin makes someone hungry. The question is whether a supported psychedelic therapy model may help some people relate differently to fear, control, body image, and change.
What the 2023 feasibility study found
A 2023 Nature Medicine study looked at psilocybin therapy in a small group of adult female participants with anorexia nervosa or partial remission. The study focused on safety, tolerability, and feasibility. It reported no clinically significant changes in ECG, vital signs, or suicidality during the primary safety period, while also noting laboratory findings such as temporary asymptomatic hypoglycemia in two participants. [2] Clinical trial Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study doi:10.1038/s41591-023-02455-9
That is useful early information. But it is not a large proof-of-effectiveness study. It was open-label, small, and exploratory. In plain terms: it helped researchers ask better next questions, but it did not settle the matter.
What the 2026 pilot study adds
A 2026 British Journal of Psychiatry pilot study looked at adult females with anorexia nervosa receiving psilocybin therapy alongside talk therapy and treatment as usual. The study reported improvements in eating-disorder symptoms and motivation to change, but also found large variation in how well those changes lasted. Two serious adverse events involving one participant occurred during later follow-up and were reported in the study. [3] Clinical trial Psilocybin therapy for adult females with anorexia nervosa: pilot study doi:10.1192/bjp.2026.10687
That combination matters. A public article must hold both sides at the same time: the study showed early signals worth studying, and it also showed why this population needs careful monitoring, follow-up, and larger research.
What “promising” does and does not mean
Promising does not mean proven. Promising means the early signal is strong enough to study more carefully.
For anorexia, that distinction is critical. A person may be medically fragile even when they appear functional. A person may also be dealing with depression, anxiety, trauma, obsessive thoughts, substance use concerns, or suicide risk. Those are not side issues. They affect safety, consent, and follow-up.
The 2025 systematic review described the evidence base as early and limited, while noting registered trials that may add more information over time. [4] Systematic review Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials doi:10.1007/s40519-025-01771-y
Why this is not a microdosing story
The anorexia studies discussed here are supervised therapy studies. They are not microdosing studies.
That matters because public readers often collapse everything into one word: mushrooms. Clinical psilocybin therapy, microdosing, retreat settings, and informal personal use are not the same thing. Results from one setting do not automatically travel to another.
What this does not mean
This article does not recommend psilocybin for anorexia. It does not give dosing advice. It does not suggest replacing treatment. It does not say a person with anorexia is a candidate for psychedelic therapy.
It means only this: anorexia is being studied in careful clinical settings, and the early evidence needs to be explained without hype.
The bottom line
Psilocybin-and-anorexia research is important, but it is not ready for broad public claims.
The right tone is cautious interest. The right message is: follow the research, protect vulnerable people, and keep eating-disorder care in qualified hands.
Why “well tolerated” is not the same as “risk-free”
Research papers often use the phrase “well tolerated.” That means the study team did not observe certain safety problems in the way the study measured them. It does not mean the intervention is safe for everyone. It does not mean risk disappears outside the study.
For anorexia, this distinction matters even more. A person may have medical risk that is not obvious. They may also be dealing with fear, shame, secrecy, or pressure from others. A clinical study can screen and monitor for some of those concerns. A public reader cannot copy that structure at home.
Why psychological support is part of the story
The published anorexia studies did not simply give psilocybin and walk away. They included psychological support. That support helps explain why the findings cannot be separated from the clinical model. NCCIH also describes support, mental state, and setting as important parts of psychedelic-assisted therapy safety. [5] Government Psilocybin for Mental Health and Addiction: What You Need To Know Link →
So the careful wording is not “psilocybin did X.” The careful wording is “psilocybin-assisted therapy was studied in this small clinical context.”